5 July 2018
Healthcare need already outstrips offer in Asia–Pacific and the gap will grow with continued increases in income, population, disease burdens, and general awareness of health......
19 February 2018
An international study, conducted by the National Cancer Institute (INCa), uses information from the Prismaccess and Evalumade databases. Its purpose is to answer two essential......
Prismaccess contains a comprehensive, detailed record of HTA authorities’ decisions extracted into easy to navigate summaries.
Prismaccess allows you to identify key data and comparator products performances allowing you to build your Pricing & Reimbursement dossier in accordance with the needs of the regulators and payers.
Prismaccess provides data and information on all pharma & biotech products during initial and subsequent evaluations by national authorities on HTA markets.
Prioritis is a global provider in market access solutions for pharmaceutical, biotechnology and medical devices. Prioritis undertakes support for pricing and reimbursement processes for new innovative drugs, extension of indications and reassessment of therapeutic areas.
Evalumade is a platform dedicated to market access leaders, offering clear top-level visual information about HTA decisions. It is a unique responsive, graphical interface constructed to facilitate the consultation and the extraction of HTA data.